CervoMed Management to Present at H.C. Wainwright Neuro Summit

CervoMed Inc. announced that its management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on Monday, June 15, 2026. The fireside chat is scheduled for 7:00 – 7:30 AM ET and will be available via webcast. The company also provided updates on its clinical pipeline, noting that the initiation of a Phase 3 trial for neflamapimod in DLB is contingent on partnership or financing, and anticipates interim biomarker data for its nfvPPA Phase 2a trial in early Q4 2026, with first patient dosing for EXPERTS-ALS Phase 2a trial also in Q4 2026.